Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$22MCash on Hand
10.2mo Cash Runway
Follow AZR by emailGet an email when AZR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AZR, unsubscribe in one click. Privacy
📣 What AZR Says Is Next
first half of 2027 · “Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.” Corporate Highlights”
Company press release, Nov 12, 2026 · SEC filing
first half of 2027 · “Azora expects to advance AT177 into a Phase 1 clinical trial in the first half of 2027.”
Company press release, Oct 28, 2026 · SEC filing
second half of 2027 · “AT177 is currently in IND-enabling studies, with an investigational new drug (“IND”) filing planned for the first half of 2027, initiation of a Phase 1a single- and multiple-ascending-dose (“SAD/MAD”) clinical trial planned to commence in the second half of 2027, followed by a Phase 1b proof-of-concept study in UC patients.”
Company press release, Aug 17, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Financing Azora Therapeutics filed a shelf registration for up to $250,000,000 of common stock, preferred stock, debt securities, warrants and units, with a $20,000,000 at-the-market sales agreement with Jefferies LLC. The offering terms and amounts for any specific sale will be set in later prospectus supplements. Form S-3 · SEC filing
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 net loss of $64.6 million, or $4.52 per share, including a $57.1 million non-cash charge on milestone warrant liability; cash was $22.0 million at September 30, 2026, down from $28.7 million. Company began trading on Nasdaq as AZR and plans AT177 IND submission and Phase 1a start in first half 2027. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Leadership Azora Therapeutics appointed Aida Habtezion, M.D., Paul Hastings and Thomas Soloway to its board effective November 3, 2026, and reconstituted its audit, compensation and nominating committees. Non-employee director compensation has not been finalized and no equity awards were granted. Directors J. Form 8-K · SEC filing
Oct 28, 2026 ·
Leadership Azora Therapeutics (formerly Adial Pharmaceuticals) named Matthew Davidson, Ph.D. CEO, and Celia Economides CFO, replacing Cary Claiborne and Vinay Shah, whose employment ended, with severance subject to a release. Julie Saiki, Ph.D. was named Chief Strategy Officer. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2023 · Phase 1 · Results Expected · Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AZR holds $22M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.5M/quarter from operations,
an estimated runway of 10.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 10 months +30
ATM program on file since Nov 2026 +15
Shelf registration (S-3, Nov 2026) +10
Going-concern doubt in the latest 10-Q +15The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Nov 17, 2026 · Shelf registration with ATM program, up to $20M · S-3
Share count 14,286,311 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AZR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AZR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.